<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04731844</url>
  </required_header>
  <id_info>
    <org_study_id>UMLT20123</org_study_id>
    <nct_id>NCT04731844</nct_id>
  </id_info>
  <brief_title>Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer</brief_title>
  <official_title>Efficacy of Curcumin and Piperine in Patients on Active Surveillance for Either Monoclonal Gammopathy of Unknown Significance (MGUS), Low-risk Smoldering Multiple Myeloma (SMM) or Early Stage Prostate Cancer: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a&#xD;
      day in early stage prostate cancer patient undergoing active surveillance or patients on&#xD;
      observation for MGUS/ low-risk smoldering myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether the supplement of curcumin plus peperine&#xD;
      can prevent or delay the progression of prostate cancer, monoclonal gammopathy of unknown&#xD;
      significant, or low-risk smoldering myeloma into a more aggressive cancer which requires&#xD;
      treatment. The investigator will be evaluating a marker in patients blood called MIC-1 to&#xD;
      determine whether it could be a useful predictor of whether the disease is improving or&#xD;
      progressing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate of Curcumin &amp; Piperine supplementation in patients on AS for either early stage prostate cancer or MGUS.</measure>
    <time_frame>From date of enrollment until the date of first documented response assessed up to 12 months</time_frame>
    <description>Measure of time from study enrollment until response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
    <description>Measure of time from study enrollment until progression.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Smoldering Multiple Myeloma (SMM)</condition>
  <condition>Monoclonal Gammopathy of Undetermined Significance</condition>
  <arm_group>
    <arm_group_label>Prostate Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Smoldering Multiple Myeloma (SMM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monoclonal Gammopathy of Unknown Significance (MGUS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin plus Piperine</intervention_name>
    <description>Curcumin with piperine is a well-tolerated over-the-counter supplement.</description>
    <arm_group_label>Monoclonal Gammopathy of Unknown Significance (MGUS)</arm_group_label>
    <arm_group_label>Prostate Cancer</arm_group_label>
    <arm_group_label>Smoldering Multiple Myeloma (SMM)</arm_group_label>
    <other_name>Curcumin C3 Complex®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient or a legally authorized representative must provide study-specific&#xD;
             informed consent prior to study entry.&#xD;
&#xD;
          -  Age ≥ 18 years of age.&#xD;
&#xD;
          -  Karnofsky performance status (KPS) of ≥ 70%.&#xD;
&#xD;
          -  Subjects with either 1) non-metastatic biopsy proven adenocarcinoma of the prostate&#xD;
             who have chosen AS the treatment option for their prostate cancer or 2) have the&#xD;
             diagnosis of either MGUS or low-risk SMM and are currently on observation alone.&#xD;
&#xD;
          -  For patients with MGUS or low-risk SMM, diagnosis must be according to the definition&#xD;
             of the International Myeloma Working Group (IMWG).&#xD;
&#xD;
               1. MGUS: serum M-protein &lt;3.0g/dL, &lt;10% clonal plasma cells (PCs) in the bone&#xD;
                  marrow, and absence of end-organ damage (CRAB criteria) that can be attributed to&#xD;
                  the plasma cell disorder.&#xD;
&#xD;
               2. SMM: serum M-protein of ≥3.0g/dL or a proportion of clonal PCs in the BM of ≥10%&#xD;
                  but &lt;60%, and no evidence of end organ damage as described below.&#xD;
&#xD;
                    -  Absence of end organ damage is defined by absence of CRAB criteria:&#xD;
&#xD;
                         -  C: Absence of hypercalcemia, defined as calcium ≤11mg/dL.&#xD;
&#xD;
                         -  R: Absence of renal failure, defined as serum creatinine ≤2.0mg/dL.&#xD;
&#xD;
                         -  A: Absence of anemia, defined as hemoglobin ≥10g/dL.&#xD;
&#xD;
                         -  B: Absence of lytic bone lesions per IMWG recommendations: One of&#xD;
                            either PET-CT, low-dose whole-body CT, or whole- body MRI. Increased&#xD;
                            uptake on PET-CT alone is not adequate for the diagnosis of multiple&#xD;
                            myeloma; evidence of underlying osteolytic bone destruction is needed&#xD;
                            on the CT portion of the examination.&#xD;
&#xD;
          -  At least one of the risk factors below that portends for an increased risk of&#xD;
             progression to MM:&#xD;
&#xD;
               -  Abnormal serum free light chain ratio.&#xD;
&#xD;
               -  M-spike ≥2.0g/dL.&#xD;
&#xD;
               -  ≥ 20% bone marrow clonal plasma cells.&#xD;
&#xD;
               -  Immunoparesis ≥20% reduction from institutional normal standard of uninvolved&#xD;
                  immunoglobulins.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Currently taking supplements containing either curcumin or piperine.&#xD;
&#xD;
          -  Plan to start any additional over the counter supplements prior to or during trial&#xD;
             period.&#xD;
&#xD;
          -  For prostate cancer patients must not be planning to undergoing primary curative&#xD;
             therapy for their prostate cancer (radiation, surgery, brachytherapy).&#xD;
&#xD;
          -  For MGUS/ SMM patients, must not have had evidence of disease progression which might&#xD;
             require treatment during the one-year study period.&#xD;
&#xD;
          -  Other: symptomatic plasma cell leukemia, amyloidosis, POEMS syndrome (polyneuropathy,&#xD;
             organomegaly, endocrinopathy, monoclonal protein).&#xD;
&#xD;
          -  Subject is pregnant or breast feeding, or planning to become pregnant during the&#xD;
             treatment period.&#xD;
&#xD;
          -  Evidence of any of the following conditions per subject self-report or medical chart&#xD;
             review: Major surgery or significant traumatic injury occurring within 4 weeks before&#xD;
             enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Van Veldhuizen</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester Wilmot Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris LeFeber</last_name>
    <phone>(585) 275-0407</phone>
    <email>WCICTOResearch@URMC.Rochester.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Chris LeFeber</last_name>
      <phone>585-275-0407</phone>
      <email>WCICTOResearch@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Van Veldhuizen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Peter Van Veldhuizen</investigator_full_name>
    <investigator_title>Professor - Department of Medicine , Hematology/Oncology (SMD)</investigator_title>
  </responsible_party>
  <keyword>curcumin</keyword>
  <keyword>peperine</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Smoldering Multiple Myeloma (SMM)</keyword>
  <keyword>Monoclonal Gammopathy of Undetermined Significance (MGUS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Smoldering Multiple Myeloma</mesh_term>
    <mesh_term>Paraproteinemias</mesh_term>
    <mesh_term>Monoclonal Gammopathy of Undetermined Significance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
    <mesh_term>Piperine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

